Source-grounded facts extracted from VERTEX PHARMACEUTICALS INC / MA's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
VERTEX PHARMACEUTICALS INC / MA shareholders approved Shareholder proposal regarding shareholder right to act by written consent at the 2026-05-13 meeting.
“Based upon the following votes, the shareholders approved a shareholder proposal regarding shareholder right to act by written consent:”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Approval of the Company's 2026 Stock and Option Plan at the 2026-05-13 meeting.
“Based upon the following votes, the shareholders approved the Company's 2026 Stock and Option Plan.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory approval of 2025 named executive officer compensation program at the 2026-05-13 meeting.
“Based upon the following votes, the shareholders approved, on an advisory basis, the 2025 compensation program for the Company's named executive officers:”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2026 at the 2026-05-13 meeting.
“Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026:”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of 10 directors to serve until 2027 annual meeting at the 2026-05-13 meeting.
“Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider and Nancy Thornberry to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2027”
VERTEX PHARMACEUTICALS INC / MA reported FY 2026 results: revenue $12.95 billion to $13.1 billion. Guidance reaffirmed.
“Vertex today reiterated full year 2026 financial guidance. Vertex's total revenue guidance of $12.95 billion to $13.1 billion”
VERTEX PHARMACEUTICALS INC / MA reported Q1 2026 results: revenue $2.99 billion, net income $1.0 billion.
“Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 —”
Suketu Upadhyay departed as Director at VERTEX PHARMACEUTICALS INC / MA.
“Suketu Upadhyay informed the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the "2026 Annual Meeting").”
Duncan J. McKechnie was appointed as Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA.
“the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company”
Charles F. Wagner, Jr. was appointed as Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.
“The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company”
Stuart A. Arbuckle retired as Executive Vice President and Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.
“On February 10, 2025, Vertex Pharmaceuticals Incorporated (the “Company”) announced the retirement of Stuart A. Arbuckle, the Company’s Executive Vice President and Chief Operating Officer, effective on July 1, 2025.”
VERTEX PHARMACEUTICALS INC / MA shareholders rejected Shareholder proposal regarding a report on racial and gender pay gaps at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders did not approve a shareholder proposal regarding a report on racial and gender pay gaps: For Against Abstain Non-Votes 63,865,687 157,637,997 694,435 11,540,149”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Shareholder proposal regarding a special shareholder meeting improvement at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders approved a shareholder proposal regarding a special shareholder meeting improvement: For Against Abstain Non-Votes 160,438,357 61,494,550 265,212 11,540,149”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory approval of 2023 compensation program for named executive officers at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders approved, on an advisory basis, the 2023 compensation program for the Company's named executive officers: For Against Abstain Non-Votes 202,098,575 19,223,784 875,760 11,540,149”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2024 at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: For Against Abstain Non-Votes 229,460,523 3,987,619 290,126 0”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Suketu Upadhyay as director at the 2024-05-15 meeting.
“178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: For Against Abstain Non-Votes 229,460,523 3,987,619 290,126 0 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Nancy Thornberry as director at the 2024-05-15 meeting.
“186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Jennifer Schneider as director at the 2024-05-15 meeting.
“6 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Bruce Sachs as director at the 2024-05-15 meeting.
“,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Diana McKenzie as director at the 2024-05-15 meeting.
“,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Jeffrey Leiden as director at the 2024-05-15 meeting.
“08,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Michel Lagarde as director at the 2024-05-15 meeting.
“gainst Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Reshma Kewalramani as director at the 2024-05-15 meeting.
“nual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Alan Garber as director at the 2024-05-15 meeting.
“as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Lloyd Carney as director at the 2024-05-15 meeting.
“neider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No.”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay as directors at the 2024-05-15 meeting.
“Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149”
VERTEX PHARMACEUTICALS INC / MA reported full year 2024 results: revenue 10.55 to 10.75 billion. Guidance reaffirmed.
“Vertex today reiterated its full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion.”
VERTEX PHARMACEUTICALS INC / MA reported first quarter ended March 31, 2024 results: revenue 2.69 billion.
“as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2024 Financial Results — Product revenue of $2.69 billion, a 13% i ncrease compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA”
VERTEX PHARMACEUTICALS INC / MA entered into Agreement and Plan of Merger with Alpine Immune Sciences, Inc. valued at $65.00 per share (effective 2024-04-10).
“On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).”
VERTEX PHARMACEUTICALS INC / MA updated its the fourth quarter and full year ended December 31, 2023 guidance (raised).
“On February 5, 2024, we issued a press release in which we reported our consolidated financial results for the three and twelve months ended December 31, 2023.”
Nancy Thornberry was appointed as member of the board of directors at VERTEX PHARMACEUTICALS INC / MA.
“On December 5, 2023, Nancy Thornberry was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”).”
VERTEX PHARMACEUTICALS INC / MA updated its full year 2023 guidance (raised).
“Vertex today raised its full year 2023 CF product revenue guidance to approximately $9.85 billion.”
VERTEX PHARMACEUTICALS INC / MA reported third quarter ended September 30, 2023 results: revenue $2.48 billion. Guidance raised.
“as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports Third Quarter 2023 Financial Results — Product revenue of $2.48 billion, a 6% increase compared to Q3 2022 — — Company raises full year 2023 product revenue guidance to approximately $9.85 billion — — U.S. FDA Advisory Committee meeting for exa-cel”
Michel Lagarde was appointed as Director at VERTEX PHARMACEUTICALS INC / MA.
“On October 3, 2023, Michel Lagarde was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”), effective on October 5, 2023.”
VERTEX PHARMACEUTICALS INC / MA reported the second quarter ended June 30, 2023 results: revenue $2.49 billion. Guidance raised.
“Vertex Reports Second Quarter 2023 Financial Results — Product revenue of $2.49 billion”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-05-17 meeting.
“Proposal No. 4: Based upon the following votes, the shareholders recommended, on an advisory basis, to hold future advisory votes to approve executive compensation on an annual basis: 1 Year 2 Years 3 Years Abstain Non-Votes 222,845,689 100,872 1,607,838 109,401 9,826,329”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory approval of 2022 compensation program for named executive officers at the 2023-05-17 meeting.
“Proposal No. 3 : Based upon the following votes, the shareholders approved, on an advisory basis, the 2022 compensation program for the Company's named executive officers: For Against Abstain Non-Votes 200,867,116 23,641,105 155,579 9,826,329”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2023 at the 2023-05-17 meeting.
“Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023: For Against Abstain Non-Votes 226,512,223 7,826,181 151,725 0”
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of the nine nominees to serve as directors at the 2023-05-17 meeting.
“Proposal No. 1 : Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Terrence Kearney, Reshma Kewalramani, Jeffrey Leiden, Diana McKenzie, Bruce Sachs and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2024: For Against Abstain Non-Votes Sangeeta Bhatia 222,080,665 2,466,298 116,837 9,826,329 Lloyd Carney 209,020,156 15,522,060 121,584 9,826,329 Alan Garber 222,238,564 2,300,900 124,336 9,826,329 Terrence Kearney 212,386,123 12,155,694 121,983 9,826,329 Reshma Kewalramani 222,944,919 1,605,123 113,758 9,826,329 Jeffrey Leiden 216,063,881 7,824,259 775,660 9,826,329 Diana McKenzie 222,081,247 2,466,571 115,982 9,826,329 Bruce Sachs 203,818,027 20,714,176 131,597 9,826,329 Suketu Upadhyay 222,991,778 1,551,263 120,759 9,826,329”
VERTEX PHARMACEUTICALS INC / MA reported the first quarter ended March 31, 2023 results: revenue $2.37 billion. Guidance reaffirmed.
“as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2023 Financial Results — Product revenue of $2.37 billion, a 13% increase compared to Q1 2022 — — Company reiterates full year 2023 financial guidance, including product revenue guidance of $9.55 to $9.7 billion — — TRIKAFTA approved in”
VERTEX PHARMACEUTICALS INC / MA reported Twelve Months Ended December 31, 2022 results: revenue $ 8,931, net income $ 3,322, EPS $ 12.82. Guidance initiated.
“Product revenues, net $ 2,303 $ 2,073 11% $ 8,931 $ 7,573 18% TRIKAFTA/KAFTRIO $ 2,022 $ 1,693 $ 7,687 $ 5,697 SYMDEKO/SYMKEVI $ 34 $ 80 $ 180 $ 420 ORKAMBI $ 111 $ 147 $ 511 $ 772 KALYDECO $ 136 $ 152 $ 553 $ 684 GAAP operating income $ 1,034 $ 878 18% $ 4,307 $ 2,782 55% Non-GAAP operating income* $ 1,150 $ 997 15% $ 4,793 $ 3,232 48% GAAP net income $ 819 $ 770 6% $ 3,322 $ 2,342 42% Non-GAAP net income* $ 978 $ 777 26% $ 3,855 $ 2,513 53% GAAP net income per share - diluted $ 3.15 $ 3.00 5% $ 12.82 $ 9.01 42%”
VERTEX PHARMACEUTICALS INC / MA reported Three Months Ended December 31, 2022 results: revenue $ 2,303, net income $ 819, EPS $ 3.15. Guidance initiated.
“Product revenues, net $ 2,303 $ 2,073 11% $ 8,931 $ 7,573 18% TRIKAFTA/KAFTRIO $ 2,022 $ 1,693 $ 7,687 $ 5,697 SYMDEKO/SYMKEVI $ 34 $ 80 $ 180 $ 420 ORKAMBI $ 111 $ 147 $ 511 $ 772 KALYDECO $ 136 $ 152 $ 553 $ 684 GAAP operating income $ 1,034 $ 878 18% $ 4,307 $ 2,782 55% Non-GAAP operating income* $ 1,150 $ 997 15% $ 4,793 $ 3,232 48% GAAP net income $ 819 $ 770 6% $ 3,322 $ 2,342 42% Non-GAAP net income* $ 978 $ 777 26% $ 3,855 $ 2,513 53% GAAP net income per share - diluted $ 3.15 $ 3.00 5% $ 12.82 $ 9.01 42%”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.